Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetic and Oncology Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for UTX/KDM6A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | UTX/KDM6A Recombinant Protein (Active Domain / Full Length) High purity (>95%), Endotoxin controlled. Sequence Verified by MS. Suitable for enzymatic and binding assays. |
View UTX Products |
| Gene Delivery | UTX/KDM6A Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and rescue assays. |
View UTX Products |
| Benchmark Ab | Anti-UTX/KDM6A Recombinant Antibody Recombinant positive control for Western Blot, ChIP, and IP validation. |
View UTX Products |
| Validator | UTX/KDM6A siRNA Set Target-specific knockdown verification in target validation studies. |
View UTX Products |
| Related Target A | KDM6B (JMJD3) Highly homologous H3K27 demethylase. Essential for selectivity profiling and off-target screening. |
View KDM6B Products |
| Related Target B | EZH2 The primary H3K27 methyltransferase. Crucial for studying epigenetic balance and synthetic lethal combinations. |
View EZH2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Homology Overlap (Selectivity vs KDM6B) | High-purity human recombinant KDM6A and KDM6B catalytic domains available for parallel screening. |
| Demethylase Activity Detection | Sequence-verified active domains optimized for H3K27me3 peptide-based demethylation assays. |
| Lack of Controls | Sequence-validated recombinant benchmark antibodies and positive control expression plasmids. |
| False Positives in Knockdown | Sequence-verified multi-target siRNA sets to ensure specific phenotype correlation. |
Live UTX/KDM6A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of UTX (KDM6A) represents a highly nuanced frontier in epigenetic medicine. Unlike traditional oncogenic drivers, UTX behaves primarily as a tumor suppressor in many solid tumors (e.g., bladder, pancreatic, and colorectal cancers) due to its role in chromatin remodeling and cell differentiation. However, in specific contexts—such as estrogen receptor-positive (ER+) breast cancer, certain leukemias, and inflammatory diseases—UTX enzymatic activity or its non-catalytic scaffolding interactions promote disease progression.
The race for UTX/KDM6A therapeutics is shifting focus from non-selective pan-KDM inhibitors to highly selective small molecules, PROTAC degraders, and combination regimens utilizing synthetic lethal relationships (such as dual EZH2/KDM6 inhibition). As first-generation molecules progress through pre-clinical validation, the next wave of R&D is targeting the specific disruption of the UTX-COMPASS complex or the selective degradation of KDM6 proteins to address both demethylase-dependent and demethylase-independent oncogenic functions.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic & Biotech Consortia | ER+ Breast Cancer, Autoimmune Diseases | High-throughput enzyme inhibition assays (Requires high-purity catalytic KDM6A domain). |
| PROTAC / Degraders | Targeted Protein Degradation (TPD) Biotechs | Multiple Myeloma, Solid Tumors | Ternary complex formation assays (Requires full-length native UTX and sequence-verified tag designs). |
| Synthetic Lethality Screen | Oncology-focused Pharma | ARID1A-mutant cancers, Bladder Cancer | Target validation and rescue assays (Requires Lentivirus Promise-ORF for stable cell line generation). |